Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
- PMID: 31926059
- DOI: 10.1002/ejhf.1708
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
Abstract
Type 2 diabetes (T2D) is associated with an increased risk of heart failure (HF), with recent reports indicating that HF with preserved ejection fraction (HFpEF) may be more common than HF with reduced ejection fraction (HFrEF) in patients with T2D. T2D and HF result in worse outcomes than either disease alone. Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) have significantly improved HF outcomes in patients with T2D and may represent a new therapeutic alternative for patients with T2D at risk for or with HF. Current guidelines recommend prevention of HF through risk factor management. Once developed, treatment of HFrEF should include neurohormonal and haemodynamic modulations; however, there are no specific treatments available for HFpEF. SGLT-2is are the first class of glucose-lowering therapy to prevent HF in clinical trials and real-world studies in patients with T2D (with or without established cardiovascular disease and with or without baseline HF). Mechanistic studies suggest that SGLT-2is have beneficial effects on both systolic and diastolic function and additional systemic effects that could benefit HF outcomes. In patients with HFrEF, SGLT-2i treatment as add-on to standard HF therapy has had beneficial effects on HF outcomes, irrespective of T2D status. These results and those of ongoing outcomes trials with SGLT-2is may help establish this drug class as a treatment for HF in patients with HFrEF and HFpEF, as well as HF in patients without T2D.
Keywords: Cardiovascular disease; Heart failure; Sodium-glucose co-transporter-2 inhibitors; Type 2 diabetes.
© 2020 European Society of Cardiology.
Similar articles
-
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9. Adv Ther. 2022. PMID: 34881413 Free PMC article. Review.
-
Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678. Diabetes Obes Metab. 2019. PMID: 31081589 Review.
-
Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.Am J Med. 2024 Feb;137(2S):S25-S34. doi: 10.1016/j.amjmed.2023.04.019. Am J Med. 2024. PMID: 38184323 Review.
-
Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.Heart Fail Rev. 2024 Jan;29(1):207-217. doi: 10.1007/s10741-023-10363-w. Epub 2023 Nov 2. Heart Fail Rev. 2024. PMID: 37917192 Review.
-
Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.Diabetes Metab Syndr. 2021 Jan-Feb;15(1):351-359. doi: 10.1016/j.dsx.2021.01.006. Epub 2021 Jan 20. Diabetes Metab Syndr. 2021. PMID: 33503584
Cited by
-
A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction.Cureus. 2024 Apr 1;16(4):e57380. doi: 10.7759/cureus.57380. eCollection 2024 Apr. Cureus. 2024. PMID: 38694659 Free PMC article. Review.
-
[Diabetes and Heart Failure].Arch Peru Cardiol Cir Cardiovasc. 2020 Mar 30;1(1):6-14. doi: 10.47487/apcyccv.v1i1.5. eCollection 2020 Jan-Mar. Arch Peru Cardiol Cir Cardiovasc. 2020. PMID: 38571972 Free PMC article. Review. Spanish.
-
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.Int J Mol Sci. 2024 Feb 20;25(5):2484. doi: 10.3390/ijms25052484. Int J Mol Sci. 2024. PMID: 38473732 Free PMC article. Review.
-
Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery.Acta Pharmacol Sin. 2024 Jan;45(1):23-35. doi: 10.1038/s41401-023-01152-0. Epub 2023 Aug 29. Acta Pharmacol Sin. 2024. PMID: 37644131 Review.
-
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.Life (Basel). 2023 Apr 14;13(4):1012. doi: 10.3390/life13041012. Life (Basel). 2023. PMID: 37109541 Free PMC article. Review.
References
-
- Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschope C, Hoes AW, Seferovic JP, Logue J, McDonagh T, Riley JP, Milinkovic I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJ. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-872.
-
- Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526-1534.
-
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.
-
- Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 2018;138:458-468.
-
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous